Patents by Inventor Nicola Neff

Nicola Neff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
    Patent number: 6310040
    Abstract: Disclosed is a method for promoting retinal neuronal survival in a mammal, wherein the neuronal cells are at risk of dying. The method comprises administering to the mammal an effective dose of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; or a functional derivative of IGF-II.
    Type: Grant
    Filed: October 15, 1992
    Date of Patent: October 30, 2001
    Assignee: Cephalon, Inc.
    Inventors: Donna Bozyczko-Coyne, Nicola Neff, Michael E. Lewis, Mohamed A. Iqbal
  • Treating disorders by application of insulin-like growth factors and analogs
    Patent number: 5776897
    Abstract: A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: July 7, 1998
    Assignee: Cephalon, Inc.
    Inventors: Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Nicola Neff, Mohamed Iqbal
  • Protein kinase inhibitors for treatment of neurological disorders
    Patent number: 5756494
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 26, 1998
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • Protein kinase inhibitors for treatmen of neurological disorders
    Patent number: 5741808
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: April 21, 1998
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • Treating disorders by application of insulin-like growth factors and analogs
    Patent number: 5703045
    Abstract: A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 30, 1997
    Assignee: Cephalon, Inc.
    Inventors: Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Nicola Neff, Mohamed Iqbal
  • Treating disorders by application of insulin-like growth factors and analogs
    Patent number: 5652214
    Abstract: A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method including the step of administering to the mammal one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.
    Type: Grant
    Filed: October 7, 1992
    Date of Patent: July 29, 1997
    Assignee: Cephalon, Inc.
    Inventors: Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Nicola Neff, Mohamed Iqbal
  • Protein kinase inhibitors for treatment of neurological disorders
    Patent number: 5621101
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 15, 1997
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • K-252a derivatives for treatment of neurological disorders
    Patent number: 5621100
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: April 15, 1997
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
    Patent number: 5468872
    Abstract: Functional K-252a derivatives are used to enhance trk phosphorylation and to potentiate the activity of neurotrophin-3 (NT-3). These compounds can be used to treat neurological disorders, alone or in combination with NT-3.
    Type: Grant
    Filed: September 16, 1993
    Date of Patent: November 21, 1995
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Marcie A. Glicksman, David P. Rotella, Nicola Neff, Chikara Murakata
  • Selected protein kinase inhibitors for the treatment of neurological disorders
    Patent number: 5461146
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. Also, a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: October 24, 1995
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman